Skip to main content
    J

    JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.63
    +0.13 (+3.71%)

    Market Cap: $557.18M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported revenue of $20.69M for the fiscal year ended Sep 30, 2025, down 12.0% from the year before. That year, net income was $1.19M with a net margin of 5.8%, operating cash flow was $2.90M and free cash flow was -$3.73M. The quarter ended Jun 30, 2026 had revenue of $8.92M and net income of -$107.73K.

    Revenue and Margins

    The operating margin was 2.9% in the fiscal year ended Sep 2025, the lowest of the 8 years shown. Over the 7 years to Sep 2025, revenue fell from $20.91M, a compound annual decline of 0.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2025$20.69M-12.0%29.2%2.9%5.8%
    Sep 2024$23.50M+18.6%40.4%15.5%15.6%
    Sep 2023$19.82M+3.3%34.2%14.5%14.5%
    Sep 2022$19.19M-7.6%32.3%11.1%14.1%
    Sep 2021$20.76M+28.2%30.6%12.7%12.7%
    Sep 2020$16.19M-20.5%34.0%14.5%13.6%
    Sep 2019$20.37M-2.6%36.9%21.6%17.9%
    Sep 2018$20.91MN/A36.6%20.2%17.6%
    Annual, fiscal years ended Sep 2018 to Sep 2025

    Income Statement

    In the fiscal year ended Sep 2025, net income fell 67.7% from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
    Revenue$20.69M$23.50M$19.82M$19.19M$20.76M$16.19M$20.37M$20.91M
    Cost of revenue$14.64M$14.00M$13.04M$12.99M$14.40M$10.70M$12.86M$13.25M
    Gross profit$6.04M$9.50M$6.78M$6.20M$6.36M$5.50M$7.51M$7.66M
    Research and development$1.56M$1.50M$1.54M$1.89M$1.57M$1.26M$1.13M$1.20M
    Operating income$608.18K$3.64M$2.87M$2.13M$2.63M$2.35M$4.40M$4.23M
    Net income$1.19M$3.68M$2.88M$2.71M$2.63M$2.21M$3.65M$3.68M
    EBITDA$958.86K$3.98M$3.09M$3.11M$3.24M$2.79M$4.75M$4.60M
    Fiscal years ended Sep 2018 to Sep 2025

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$8.92M$10.81M$4.94M$9.88M$4.94M$12.95M$6.47M$10.56M$5.28M$9.57M$4.78M$10.25M
    Gross profit$2.40M$3.64M$1.27M$2.53M$1.27M$5.81M$2.91M$3.80M$1.90M$3.25M$1.67M$3.63M
    Operating income-$644.45K$1.06M-$227.11K-$454.21K-$227.11K$2.41M$1.20M$1.23M$614.62K$1.10M$547.90K$1.77M
    Net income-$107.73K$1.28M-$44.50K-$89.01K-$44.50K$1.88M$940.92K$1.79M$897.05K$1.11M$555.94K$1.77M
    Last 12 quarters

    Balance Sheet

    As of Sep 2025, short-term debt of $18.91M exceeded cash and equivalents by $11.45M.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
    Total assets$53.37M$45.80M$32.90M$20.94M$21.90M$20.82M$20.36M$18.68M
    Current assets$44.14M$42.82M$31.12M$18.90M$19.42M$18.16M$17.70M$15.61M
    Cash and equivalents$7.46M$8.14M$6.93M$4.79M$3.67M$1.66M$1.94M$853.30K
    Total liabilities$23.80M$17.25M$8.92M$5.70M$7.87M$10.01M$9.66M$9.68M
    Short-term debt$18.91M$11.51MN/AN/AN/A$2.65M$2.87M$712.53K
    Shareholder equity$29.64M$28.82M$23.98M$15.24M$14.03M$10.80M$10.71M$9.00M
    Fiscal years ended Sep 2018 to Sep 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$55.84M$55.84M$53.37M$53.37M$48.52M$48.52M$48.52M$45.80M$45.80M$41.16M$41.16M$32.90M
    Total liabilities$25.69M$25.69M$23.80M$23.80M$20.77M$20.77M$20.77M$17.25M$17.25M$15.01M$15.01M$8.92M
    Cash and equivalents$9.08M$9.08M$7.46M$7.46M$11.13M$11.13M$11.13M$8.14M$8.14M$8.87M$8.87M$6.93M
    Shareholder equity$30.32M$30.32M$29.64M$29.64M$27.91M$27.91M$27.91M$28.82M$28.82M$26.24M$26.24M$23.98M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Sep 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.

    Annual

    Line itemSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018
    Operating cash flow$2.90M-$1.21M$3.11M$1.58M$5.84M$2.50M-$1.33M-$2.39M
    Capital expenditures$6.63M$1.12M$113.94K$40.17K$42.88K$142.32K$73.33K$187.68K
    Free cash flow-$3.73M-$2.33M$2.99M$1.54M$5.80M$2.36M-$1.40M-$2.58M
    Investing cash flow-$10.79M-$9.51MN/A-$120.90K-$1.07M-$1.96M$126.94K$1.96M
    Financing cash flow$7.35M$11.65M$6.91M$121.86K-$2.87M-$343.91K$2.36M-$3.19M
    Fiscal years ended Sep 2018 to Sep 2025

    Quarterly

    Line itemJun 2026Dec 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$934.42K$341.55K$2.56M$5.12M$1.28M-$1.26M-$628.65K$50.00K$25.00K$362.91K$181.46K$2.74M
    Capital expenditures$1.79M$4.58M$1.03M$2.05M$1.03M$61.27K$30.64K$83.68K$41.84K$102.92K$51.46K$11.01K
    Free cash flow-$2.72M-$4.24M$1.54M$3.07M$255.45K-$1.32M-$659.29K-$33.68K-$16.84K$259.99K$129.99K$2.73M
    Last 12 quarters

    Frequently Asked Questions About ZJYL

    What is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares' annual revenue?

    JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported revenue of $20.69M for the fiscal year ended Sep 30, 2025.

    How fast is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares' revenue growing?

    Revenue was down 12.0% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.5%.

    Is JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares profitable?

    Yes. JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares reported net income of $1.19M for the fiscal year ended Sep 30, 2025, with a net margin of 5.8%.

    How much free cash flow does ZJYL generate?

    For the fiscal year ended Sep 30, 2025, operating cash flow of $2.90M minus capital expenditures of $6.63M produced free cash flow of -$3.73M.

    How much debt does JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares have?

    The balance sheet dated Sep 30, 2025 reported short-term debt of $18.91M and cash and equivalents of $7.46M.